Apollon Formulies PLC says medicinal cannabis formulations are effective in killing breast cancer cells


The drug company said tests of its cannabis formulations and medicinal mushrooms, developed by Canadian company Aion Therapeutic, were effective in killing HER2 + breast cancer cells, the cause of about 20% of all breast cancers

According to the PLC (), a combined formulation of its medicinal cannabis treatment and the medicinal mushrooms developed by Canadian company Aion Therapeutic Inc has been effective in killing HER2 + breast cancer cells, the cause of about 20% of all breast cancers.

The pharmaceutical company said tests by the independent laboratory BIOENSIS showed that its medicinal cannabis formulations are “particularly effective” at directly killing live HER2 + cancer cells, while Aion’s medicinal mushroom formulations are most effective at stimulating T-cell production of the immune system to produce HER2 + attack and kill cancer cells.

WATCH: Dr. Barnhill of Apollon Formies, inspired by the death of his mother, to cure cancer nausea with THC-guided drugs

When the two formulations were combined, Apollon said that almost 100% of HER2 + cells were killed in 3D cell cultures.

Apollon’s cannabis formulation was developed by its subsidiary Apollon Formulies Jamaica, while the tests were conducted under a joint testing agreement between the parties under a research and development license issued by the Jamaican government’s Cannabis Licensing Authority.

“Cannabinoids have been observed to exert ‘anti-tumor’ effects in a number of ways, including killing cancer cells directly, as well as inhibiting transformed cell growth and metastasis. Apollon Jamaica uses results of its proprietary artificial intelligence-based analysis of strain genetics. Has some of its We are pleased that our formulations have been validated by independent laboratory tests to kill HER2 + breast cancer cells in 3D cell culture through direct cytotoxicity, “said Stephen, CEO of Apollon Barnhill in a Explanation.

“It is our theory that using a combination of cancer therapies, particularly those with separate treatment pathways, may have advantages over single-agent-based strategies, as they can allow for simultaneous or serial targeting of tumor growth, progression, and / or spread at different levels Levels in an effort to kill cancer cells, ”he added.